Mycobacterium tuberculosis and the host response
- PMID: 15939785
- PMCID: PMC2213264
- DOI: 10.1084/jem.20050842
Mycobacterium tuberculosis and the host response
Abstract
Mycobacterium tuberculosis remains a leading cause of morbidity and mortality worldwide. Advances reported at a recent international meeting highlight insights and controversies in the genetics of M. tuberculosis and the infected host, the nature of protective immune responses, adaptation of the bacillus to host-imposed stresses, animal models, and new techniques.
Figures




Similar articles
-
Rational design of vaccines against tuberculosis directed by basic immunology.Int J Med Microbiol. 2008 Jan;298(1-2):143-50. doi: 10.1016/j.ijmm.2007.07.004. Epub 2007 Aug 16. Int J Med Microbiol. 2008. PMID: 17702652 Review.
-
[Frontier of mycobacterium research--host vs. mycobacterium].Kekkaku. 2005 Sep;80(9):613-29. Kekkaku. 2005. PMID: 16245793 Japanese.
-
Animal Models of Tuberculosis Vaccine Research: An Important Component in the Fight against Tuberculosis.Biomed Res Int. 2020 Jan 2;2020:4263079. doi: 10.1155/2020/4263079. eCollection 2020. Biomed Res Int. 2020. PMID: 32025519 Free PMC article. Review.
-
The use of mutant mycobacteria as new vaccines to prevent tuberculosis.Tuberculosis (Edinb). 2006 May-Jul;86(3-4):203-10. doi: 10.1016/j.tube.2006.01.022. Epub 2006 Mar 20. Tuberculosis (Edinb). 2006. PMID: 16542875 Review.
-
Vaccine potential of Mycobacterium tuberculosis-specific genomic regions: in vitro studies in humans.Expert Rev Vaccines. 2009 Oct;8(10):1309-12. doi: 10.1586/erv.09.93. Expert Rev Vaccines. 2009. PMID: 19803751 No abstract available.
Cited by
-
Susceptibility to Intracellular Infections: Contributions of TNF to Immune Defense.Front Microbiol. 2020 Jul 15;11:1643. doi: 10.3389/fmicb.2020.01643. eCollection 2020. Front Microbiol. 2020. PMID: 32760383 Free PMC article. Review.
-
Attenuated Mycobacterium tuberculosis SO2 vaccine candidate is unable to induce cell death.PLoS One. 2012;7(9):e45213. doi: 10.1371/journal.pone.0045213. Epub 2012 Sep 19. PLoS One. 2012. PMID: 23028853 Free PMC article.
-
Posttransplantation tuberculosis management in terms of immunosuppressant cost: a case report in Myanmar.Korean J Transplant. 2021 Mar 31;35(1):48-52. doi: 10.4285/kjt.20.0041. Korean J Transplant. 2021. PMID: 35769623 Free PMC article.
-
Monitoring of peptide-specific and gamma interferon-productive T cells in patients with active and convalescent tuberculosis using an enzyme-linked immunosorbent spot assay.Clin Vaccine Immunol. 2012 Mar;19(3):401-10. doi: 10.1128/CVI.05544-11. Epub 2012 Jan 11. Clin Vaccine Immunol. 2012. PMID: 22237892 Free PMC article.
-
Evidence for an intramacrophage growth phase of Mycobacterium ulcerans.Infect Immun. 2007 Feb;75(2):977-87. doi: 10.1128/IAI.00889-06. Epub 2006 Dec 4. Infect Immun. 2007. PMID: 17145944 Free PMC article.
References
-
- Fields, S., and M. Johnston. 2005. Cell biology. Whither model organism research? Science. 307:1885–1886. - PubMed
-
- Pym, A.S., P. Brodin, L. Majlessi, R. Brosch, C. Demangel, A. Williams, K.E. Griffiths, G. Marchal, C. Leclerc, and S.T. Cole. 2003. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat. Med. 9:533–539. - PubMed
-
- Reed, M.B., P. Domenech, C. Manca, H. Su, A.K. Barczak, B.N. Kreiswirth, G. Kaplan, and C.E. Barry III. 2004. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature. 431:84–87. - PubMed
-
- Trivedi, O.A., P. Arora, A. Vats, M.Z. Ansari, R. Tickoo, V. Sridharan, D. Mohanty, and R.S. Gokhale. 2005. Dissecting the mechanism and assembly of a complex virulence mycobacterial lipid. Mol. Cell. 17:631–643. - PubMed
-
- Fitness, J., S. Floyd, D.K. Warndorff, L. Sichali, S. Malema, A.C. Crampin, P.E. Fine, and A.V. Hill. 2004. Large-scale candidate gene study of tuberculosis susceptibility in the Karonga district of northern Malawi. Am. J. Trop. Med. Hyg. 71:341–349. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical